Navigation Links
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
Date:12/1/2009

BETHESDA, Md., Dec. 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

Under the terms of the agreement, Bayer Schering Pharma had an option until January 5, 2010 to license a specific BiTE antibody targeting an undisclosed target. The option exercise triggers a formal collaboration between Micromet and Bayer Schering Pharma on the development of the BiTE antibody. Micromet will be primarily responsible for the preclinical development of the BiTE antibody, and will collaborate with Bayer through the completion of phase 1 clinical trials, at which point Bayer Schering Pharma will assume full control of the further development and commercialization of the BiTE antibody. Micromet will receive an option exercise fee of Euro 5 million (approx. $7.5 million), and is eligible for further milestone payments of up to Euro 285 million (approx. $426 million) in total and up to double digit royalties on net sales of the BiTE antibody. In addition, Micromet will be reimbursed for its R&D expenses.

"BiTE antibodies represent a promising approach to cancer therapy," said Dr. Karl Ziegelbauer, Head Therapeutic Research Oncology of Bayer Schering Pharma AG. "We are pleased with the progress of the program since the signing of the agreement in January of this year. We are looking forward to developing a new treatment for patients with solid tumors and to further advance novel therapeutic options in our oncology portfolio."

Jens Hennecke, Micromet's Senior Vice Presi
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
2. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
3. Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
4. Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology
5. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
6. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
7. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 2011 Reportlinker.com announces that a new market research ... Global Injectable Drug Delivery Market (2010 - 2015) ... KEY TAKE AWAYS * To ... its various sub-segments with respect to types of systems, ...
... Reportlinker.com announces that a new market research report ... European Markets for Minimally Invasive Spinal Devices ... The European minimally invasive spinal implant ... Rapid growth of the MIS interbody and MIS ...
Cached Medicine Technology:Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 2Reportlinker Adds Global Injectable Drug Delivery Market (2010 - 2015) 3Reportlinker Adds European Markets for Minimally Invasive Spinal Devices 2011 2
(Date:9/1/2015)... ... ... Dr. Trace Curry successfully placed one of the first ORBERA™ Intra-gastric Balloons in ... has approved two intra-gastric balloons, the ORBERA ™ Managed Weight Loss System and ... loss procedures available to Americans. , Dr. Curry, medical director at JourneyLite, ...
(Date:9/1/2015)... ... , ... Elizabeth Callahan, MD, founder and medical director of SkinSmart Dermatology® ... RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an immediate volumizing ... hands, delivering smooth, natural-looking results that can last up to one year in most ...
(Date:9/1/2015)... , ... September 01, 2015 , ... September is Baby ... manufacturers use safety labels and stickers to keep little ones' safety top of mind ... Safety Month has a particular focus. According to the JPMA's Baby Safety Zone website, ...
(Date:8/31/2015)... ... ... The PT Outcomes Registry is an organized system for collecting data to evaluate ... being developed by the American Physical Therapy Association (APTA). , Al Amato, PT, MBA, ... FOTO Outcomes measures as one of the primary global outcomes measures to be used ...
(Date:8/31/2015)... Oaks, CA (PRWEB) , ... August 31, 2015 ... ... recently been updated to include a wealth of information for specific translation services ... has great expertise and an incredible track record of successful work. , ITC ...
Breaking Medicine News(10 mins):Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3
... Blue Cross and Blue,Shield of Oklahoma is announcing ... medical-dental program. The program is,unique in the industry ... to create a customized plan aimed to improve ... help users optimize their overall,health by making better ...
... fingerprint associated with normal embryonic stem cells may be ... cells. The research, published by Cell Press in the ... embryonic stem cells and multiple types of human cancer ... in normal differentiated cells, a finding that may have ...
... density, reduction in fractures, study finds , , WEDNESDAY, April ... safe and effective for women with mild to moderate ... risk, according to a new study. , The use ... controversial because it wasn,t known if the drugs were ...
... 2008 The Reproductive,Science Center of New ... for Ambulatory Health Care (AAAHC/Accreditation,Association), according to ... as an accredited organization means Reproductive Science ... of rigorous and nationally recognized,standards for the ...
... Being in Top 5% Nationwide in ... ... Providence Saint Joseph,Medical Center has received the Gold Seal of Approval(TM) ... third,hospital in Los Angeles County to receive this designation., This ...
... a hospital,is crowded on admission day, children may ... have less complicated illnesses that require ongoing assessment ... does not,affect the length of stay for children ... cell crises or bacterial meningitis., "Our findings ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Oklahoma Launches an Integrated Medical-Dental Health Program 2Health News:Blue Cross and Blue Shield of Oklahoma Launches an Integrated Medical-Dental Health Program 3Health News:Module map links embryonic stem cells and cancer stem cells 2Health News:Raloxifene Safe for Women With Decreased Kidney Function 2Health News:Reproductive Science Center of New England Receives Ambulatory Health Care Accreditation 2Health News:Providence Saint Joseph Medical Named LA County's Third Primary Stroke Center 2Health News:Admission-Day Crowding May Increase Hospital Stay for Children With Less Complicated Illnesses 2
High speed, programmable refrigerated centrifuge. High efficiency separations, "Like clockwork" accuracy, aerosol containment, Accommodating, Re-Run control, Glove-Friendly membrane, centrifuge statu...
... 460 family of centrifuges ... that meets a wide ... feature high capacity, versatility ... technology and high safety ...
The Quantum performs centrifugal blood cell separations, urine separations, and sperm cell washing. 24 place angle head, variable speed, and automatic braking system, calibrated variable speed....
... centrifuge is designed especially for ... cover with safety interlock switch, ... emissions, "hold" position for continuous ... motor, maximum stability and compact, ...
Medicine Products: